# Acetyl-leucine in Post-stroke Ataxia

Study · id `cardio:ct-nct07275749` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07275749](<https://clinicaltrials.gov/study/NCT07275749>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07275749

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07275749. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2026-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07275749, source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)
- Planned start: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT07275749, source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)
- Primary completion: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07275749, source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)
- Completion: 2026-07-20 (anticipated) (ClinicalTrials.gov record NCT07275749, source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07275749, source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07275749-2025-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Acetyl-leucine in Post-stroke Ataxia
- Condition: Ischemic Stroke
- Intervention (Drug): Acetyl-Leucine
- Intervention (Drug): Placebo
- Intervention (Drug): Clopidogrel 75 Mg Oral Tablet
- Intervention (Drug): aspirin 100mg
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: edb130a6b2cdce7d8ae8c8a22495dfab640ffaaceffcdd7b7248a45f0fe912f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
